Atorvastatin affects interleukin-2 signaling by altering the lipid raft enrichment of the interleukin-2 receptor β chain

Journal of Investigative Medicine

Volumn 53, Issue 6, 2005, Pages 322-328

  Goebel, Jens ^a,b   Logan, Barbara ^a   Forrest, Kathy ^b   Mieczkowski, Alexandra ^a   Roszman, Thomas L ^c   Wills Karp, Marsha ^a  

^a CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^b UNIVERSITY OF KENTUCKY   (United States)

^c UNIVERSITY OF KENTUCKY   (United States)

Author keywords

Interleukin 2 receptor; Rafts; Statins

Indexed keywords

ATORVASTATIN; CHOLESTEROL; FLUORESCEIN ISOTHIOCYANATE; GANGLIOSIDE GM1; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOMODULATING AGENT; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR ALPHA; INTERLEUKIN 2 RECEPTOR BETA; METHYL BETA CYCLODEXTRIN; PHYTOHEMAGGLUTININ;

CELL SURFACE; CONFERENCE PAPER; CONTROLLED STUDY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IMMUNOMODULATION; IMMUNOPRECIPITATION; LIPID RAFT; PROTEIN PHOSPHORYLATION; T LYMPHOCYTE ACTIVATION;

EID: 27344459490     PISSN: 17088267     EISSN: None     Source Type: Journal    
DOI: 10.2310/6650.2005.53610     Document Type: Conference Paper

References (20)

1. Silverstein D. Indications and outcome of treatment of hyperlipidemia in pediatric allograft recipients. Pediatr Transplant 2003;7:7-10.
2. Blanco-Colio LM, Tunon J, Martin-Ventura JL, Egido J. Anti-inflammatory and immunomodulatory effects of statins. Kidney Int 2003;63:12-23.
3. Frenette PS. Locking a leukocyte integrin with statins. N Engl J Med 2001;345:1419-21.
4. Kwak B, Mulhaupt F, Myit S, Mach F. Statins as a newly recognized type of immunomodulator. Nat Med 2000;6:1399-402.
5. Youssef S, Stüve O, Patarroyo JC, et al. The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease. Nature 2002;420:78-84.
6. Paliniski W, Tsimikas S. Immunomodulatory effects of statin: mechanisms and potential impact on arteriosclerosis. J Am Soc Nephrol 2002;13:1673-81.
7. Rao R, Logan B, Forrest K, et al. Lipid rafts in cytokine signaling. Cytokine Growth Factor Rev 2004;15:103-10.
8. Liao JK. Statin therapy for cardiac hypertrophy and heart failure. J Invest Med 2004;52:248-53.
9. Goebel J, Forrest K, Morford L, Roszman T. Differential localization of IL-2- and -15 receptor chains in membrane rafts of human T cells. J Leukoc Biol 2002;72:199-206.
10. Bacon CM, McVicar DW, Ortaldo JR, et al. Interleukin-12 (IL-12) induces tyrosine phosphorylation of JAK2 and TYK2: differential use of Janus family tyrosine kinases by IL-2 and IL-12. J Exp Med 1995;181:399-404.
11. Lin JX, Leonard WL. Signaling from the IL-2 receptor to the nucleus. Cytokine Growth Factor Rev 1997;8:313-32.
12. Tuosto L, Parolini I, Schröder S, et al Organization of plasma membrane functional rafts upon T cell activation. Eur J Immunol 2001;31:345-9.
13. Patel DN, Pagani FD, Koelling TM, et al. Safety and efficacy of atorvastatin in heart transplant recipients. J Heart Lung Transplant 2002;21:204-10.
14. Krmar RT, Ferraris JR, Ramirez JA et al. Use of atorvastatin in hyperlipidemic hypertensive renal transplant recipients. Pediatr Nephrol 2002;17:540-3.
15. Argent E, Kainer G, Aitken M, et al. Atorvastatin treatment for hyperlipidemia in pediatric renal transplant recipients. Pediatr Transplant 2003;7:38-42.
16. Palinski W. Immunomodulation: a new role for statins? Nat Med 2000;6:1311-2.
17. Katano H, Pesnicak L, Cohen JI. Simvastatin induces apoptosis of Epstein-Barr virus (EBV)-transformed lymphoblastoid cell lines and delays development of EBV lymphomas. Proc Natl Acad Sci U S A 2004;10:4960-5.
18. Weitz-Schmidt G, Welzenbach K, Brinkmann V, et al. Statins selectively inhibit leukocyte function antigen-1 by binding to a novel regulatory integrin site. Nat Med 2001;7:687-92.
19. Shevach EM. CD4+CD25+ suppressor T cells: more questions than answers. Nat Rev Immunol 2002;2:389-400.
20. Malek TR. The main function of IL-2 is to promote the development of T regulatory cells. J Leukoc Biol 2003;74:961-5.